Mediastinal Grey Zone Lymphoma From the LYSA

Mediastinal grey zone lymphoma, B cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B cell lymphoma, are not well described in the literature. Investigators report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Mediastinal Grey Zone Lymphoma

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre hospitalier Lyon sud

Pierre-Bénite, Auvergne-Rhône-Alpes, 69126, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

cases with an intermediate morphology and phenotype between CHL and PMBCL were included after central pathological review

Exclusion criteria

Cases of CHL with partial CD20 expression or low expression in tumoral cells were excluded and considered as CD20-positive CHL
Exclusion of sequential form patients (with a diagnostic biopsy of PMBCL and a relapse biopsy of CHL or vise-versa) as they represent a biases for statistical analysis.

Treatment and study plan

Primary outcomes

EFS in the global population of GZL

Time frame: EFS: Event Free Survival from date of randomization until the date of first documented progression, up to 130 months

Event-free survival (EFS) was calculated from the date of diagnosis to the date of progression, a change of therapy that was not initially scheduled (radiotherapy, high-dose therapy with autologous stem cell transplantation and other unplanned treatments) or death from any cause.

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Mediastinal Grey Zone Lymphoma: Clinico-pathological Characteristics and Outcomes of 99 Patients From the LYSA

Important dates

Study start: 2013
Primary completion: 2016
Study completion: 2016
First posted: Jan 31, 2017
Registry last updated: Jan 31, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.